---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-020482"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:37:12.169869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B

## Summary
- Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).
- Gross margin 66.9% Q4 2025 vs 62.9% Q4 2024; FY2025 gross margin 64.7%.
- Oncology test volumes up 54.7% YoY in Q4 (233,300 tests) and 51.6% for FY2025.
- Full-year positive cash inflow of $107.6M; net loss $208.2M ($1.52 per diluted share).
- FY2026 guidance: revenue $2.62-2.70B, gross margin ~63-65%, positive cash inflow.

## SEC filing metadata
- accession: 0001104659-26-020482
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465926020482/0001104659-26-020482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465926020482/tm266979d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-020482
- JSON: https://secwatch.observer/filing/0001104659-26-020482.json
- Plain text: https://secwatch.observer/filing/0001104659-26-020482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.